This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TIPS ETFs to Buy for 2021 on Inflation Trade
by Sweta Killa
The COVID-19 vaccines and their availability have raised the prospect of inflation as we move ahead into the next year.
10 Best Performing Leveraged ETFs of 2020
by Sweta Killa
This year has witnessed historic twists and turns with the largest bull market turning into a bear market in March on the coronavirus outbreak, and then marking the fastest-ever recovery.
5 Beaten-Down Energy Stocks to Buy for a Turnaround in 2021
by Nilanjan Choudhury
With energy set for a strong 2021 on vaccine-led demand boost, 5 underperformers of this year - DCP Midstream (DCP), Sinopec (SNP), Vermilion Energy (VET), NOW (DNOW) and Enerplus (ERF) - are likely to rebound.
These Stocks Could Be Your Secret Santa This Christmas
by Sweta Killa
Looking for a surprise this Christmas? Bet on these stocks - BJs Wholesale (BJ), Gogo (GOGO), TRI Pointe (TPH), Penske Automotive (PAG), and Santander Consumer (SC) - for big returns.
Moderna Vaccine: The Power of mRNA Technology
by Kevin Cook
Warp speed was just the ticket to launch top COVID-19 vaccines -- and a revolution in medicine
Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) and Alexion's (ALXN) acquisition grab headlines this week.
CytoDyn (CYDY) Completes Enrollment in Phase III COVID-19 Study
by Zacks Equity Research
CytoDyn (CYDY) completes full enrollment for its phase III registrational study of Vyrologix for the treatment of patients with severe-to-critical COVID-19.
The Zacks Analyst Blog Highlights: Pfizer, Trane Technologies, United Parcel Service, FedEx and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Trane Technologies, United Parcel Service, FedEx and Moderna
Moderna (MRNA) Vaccine May Get Emergency Approval This Week
by Zacks Equity Research
An advisory committee meeting is scheduled on Dec 17 to discuss emergency use authorization for Moderna's (MRNA) COVID-19 vaccine candidate, mRNA-1273.
6 Secret Santa ETFs to Add Cheer to Your Portfolio
by Sweta Killa
While most of the ETFs have been surging over the past month, there are some hidden gems or Secret Santa as we call them that could surprise investors with big returns this Christmas based on the current trends.
Stock Market News for Dec 16, 2020
by Zacks Equity Research
Wall Street closed sharply higher on Tuesday buoyed by investors' renewed hopes for a fresh round of coronavirus-aid package by this week end.
Earn 7% Plus Yield With These ETFs
by Sanghamitra Saha
These ETFs offer at least 7% in annual yield.
5 Small-Cap Sector ETFs Beating the Russell 2000
by Sweta Killa
We have presented five ETFs that have easily crushed the Russell 2000 Index over the past three months.
Industrial Production Beats Expectations in November
by Zacks Equity Research
Industrial Production Beats Expectations in November.
Sector ETFs to Gain the Most on COVID-19 Vaccine Rollout
by Sweta Killa
The United States has geared up for the largest-ever immunization with the rollout of the COVID-19 vaccine.
Markets Swing Back Up on Vaccine Positivity
by Mark Vickery
Import Prices, Empire State and Industrial Production numbers join new positive data from the FDA on Moderna's (MRNA) vaccine candidate.
Stock Market News for Dec 15, 2020
by Zacks Equity Research
Wall Street closed mixed on Monday as investors remained concerned about recent spike in new COVID-19 cases in the United States and Eurozone.
AstraZeneca's (AZN) Triple Combo COPD Therapy Gets EU Nod
by Zacks Equity Research
AstraZeneca (AZN) gets European approval for triple combination therapy, Trixeo Aerosphere for COPD. CHMP recommends approval of trastuzumab deruxtecan for breast cancer.
Gaming ETF (BJK) Hits a New 52-Week High
by Sweta Killa
This gaming ETF hits a new 52-week high. Are more gains in store for this ETF?
CureVac (CVAC) Begins Pivotal Study on COVID-19 Vaccine
by Zacks Equity Research
CureVac (CVAC) doses the first patient in a pivotal study on its COVID-19 vaccine candidate, CVnCoV. Shares rise following this development.
5 Stocks to Win Big as Coronavirus Vaccine Rollout Begins
by Tirthankar Chakraborty
Emergency approval of COVID-19 vaccines is a boon for stocks such as Trane Technologies (TT), United Parcel Service (UPS), FedEx (FDX), Pfizer (PFE) and Moderna (MRNA). Here's why -
US Starts COVID-19 Vaccine Drive: 5 Consumer Discretionary Picks
by Ritujay Ghosh
The COVID-19 vaccine comes as a relief, indicating that the economy might bounce back in the coming days helping stocks like WilliamsSonoma (WSM), Reynolds Consumer Products (REYN) and Spectrum Brands Holdings (SPB).
Vaccines Get to America, but Congressional Relief Lacking
by Mark Vickery
Market indexes began the day solidly in the green, but a bit of bearish trepidation crept in during the day, helping the Dow and S&P 500 finish down.
Glaxo's (GSK) Rukobia Gets CHMP Nod for Heavily Pre-Treated HIV
by Zacks Equity Research
Glaxo (GSK) receives positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rukobia for treating HIV-1 infection in heavily pre-treated adult HIV patients.
Viatris (VTRS) to Cut Jobs as Part of Restructuring Initiative
by Zacks Equity Research
Viatris (VTRS) announces job cuts as part of additional details of its previously disclosed multi-year global restructuring initiative.